证券代码：003020 证券简称：立方制药 公告编号：2025-056 合肥立方制药股份有限公司独立董事 提名人声明与承诺 提名人合肥立方制药股份有限公司董事会现就提名李进华为合肥立方制药 股份有限公司第六届董事会独立董事候选人发表公开声明。被提名人已书面同意 作为合肥立方制药股份有限公司第六届董事会独立董事候选人（参见该独立董事 候选人声明）。本次提名是在充分了解被提名人职业、学历、职称、详细的工作 经历、全部兼职、有无重大失信等不良记录等情况后作出的，本提名人认为被提 名人符合相关法律、行政法规、部门规章、规范性文件和深圳证券交易所业务规 则对独立董事候选人任职资格及独立性的要求，具体声明并承诺如下事项： 一、被提名人已经通过合肥立方制药股份有限公司第五届董事会提名委员会 资格审查，提名人与被提名人不存在利害关系或者其他可能影响独立履职情形的 密切关系。 是 □ 否 如否，请详细说明：______________________________ 二、被提名人不存在《中华人民共和国公司法》第一百七十八条等规定不得 担任公司董事的情形。 是 □ 否 如否，请详细说明：_____________________ ...

证券代码：003020 证券简称：立方制药 公告编号：2025-054 合肥立方制药股份有限公司 关于召开2025年第一次临时股东大会的通知 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记 载、误导性陈述或重大遗漏。 经合肥立方制药股份有限公司（以下简称"公司"或"立方制药"）第五届董 事会第二十二次会议审议通过，决定于2025年8月29日下午14:30召开2025年第一次 临时股东大会。现将股东大会的相关事项通知如下： 一、召开会议的基本情况 1、股东大会届次：2025年第一次临时股东大会。 2、股东大会的召集人：公司第五届董事会。 公司第五届董事会第二十二次会议审议通过了《关于召开公司2025年第一次临 时股东大会的议案》。 3、会议召开的合法、合规性：本次股东大会的召开符合有关法律、行政法规、 部门规章、规范性文件、深圳证券交易业务规则和《公司章程》等规定。 4、会议召开的日期、时间： （1）现场会议召开时间：2025年8月29日（星期五）下午14:30； （2）网络投票时间： 通过深圳证券交易所交易系统投票的时间为：2025年8月29日9:15—9:25、 9:30—11:30、 ...

证券代码：003020 证券简称：立方制药 公告编号：2025-051 合肥立方制药股份有限公司 第五届董事会第二十二次会议决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 一、董事会会议召开情况 合肥立方制药股份有限公司（以下简称"公司"）第五届董事会第二十二次 会议于 2025 年 8 月 8 日以电子邮件、电话、短信等方式通知公司全体董事。会 议于 2025 年 8 月 12 日在公司会议室以现场结合通讯表决方式召开，会议应出席 董事 7 人，实际出席董事 7 人，其中以通讯方式出席会议董事 1 人，独立董事李 进华先生以通讯方式出席会议并表决。公司部分监事、高级管理人员列席了会议。 会议由公司董事长季俊虬先生主持。 本次董事会会议的召集、召开程序符合有关法律、行政法规、部门规章、规 范性文件和《公司章程》《董事会议事规则》的规定。 二、董事会会议审议情况 与会董事经过认真审议并投票表决，审议通过了如下议案： 1、《关于修订〈公司章程〉并办理工商登记的议案》 （1）同意将公司董事会成员人数由 7 名调整为 8 名，其中非独立董事 5 名 （含职工 ...

Company Performance - As of August 8, 2025, Lifan Pharmaceutical (stock code 003020) closed at 27.1 yuan, down 0.88%, with a turnover rate of 5.63% and a trading volume of 77,600 lots, amounting to 211 million yuan [1] - The latest quarterly report shows total revenue of 360 million yuan, a year-on-year increase of 7.98%, and a net profit attributable to shareholders of 38.25 million yuan, up 25.94% year-on-year [1] - The company's non-recurring net profit was 31.60 million yuan, reflecting an 11.28% year-on-year growth [1] - Financial ratios include a current ratio of 2.142, a quick ratio of 1.723, and a debt-to-asset ratio of 24.82% [1] Capital Flow - On the reporting day, the net outflow of main funds was 32.19 million yuan, accounting for 15.24% of the total transaction amount [1] - Large orders saw a net outflow of 27.09 million yuan, representing 12.82% of the transaction amount, while small orders had a net inflow of 40.26 million yuan, making up 19.06% of the transaction amount [1] Company Background - Hefei Lifan Pharmaceutical Co., Ltd. was established in 2002 and is primarily engaged in the pharmaceutical manufacturing industry [2] - The company has a registered capital of 1.9018 billion yuan and a paid-in capital of 660 million yuan [1] - The company has made investments in 11 enterprises and has participated in 5,000 bidding projects [2]

Group 1 - Yabont Chemical signed a 10-year supply strategic agreement with Jiangsu Hengrui Medicine to enhance collaboration in the pharmaceutical supply chain, effective from August 1, 2025 [1] - Wei Hua New Materials plans to acquire controlling interest in Jiangsu Heyutai Chemical to extend its product chain and improve competitiveness, currently in the planning stage [2] - Fujirey received a government subsidy of 2.0074 million yuan, expected to positively impact profits in 2025 [4] Group 2 - Hangzhou Garden won the land use rights for a plot in Yuhang District for 130 million yuan, planning to build a smart ecological design R&D headquarters with a total investment of no more than 450 million yuan [5] - Baotai's clinical trial for BAT5906, a recombinant anti-VEGF monoclonal antibody, received approval for new indications, aiming to accelerate commercialization [6] - Weisheng Information won multiple projects with a total bid amount of 110 million yuan, including significant contracts with Southern Power Grid and State Grid [8] Group 3 - Dong'an Power reported a 27.37% year-on-year increase in engine sales for July, totaling 34,500 units [13] - Hanma Technology's truck sales reached 956 units in July, marking a 42.69% year-on-year increase [14] - Jiangsu Bank's executives received regulatory approval for their positions, effective immediately [15] Group 4 - Chip Origin expects Q2 revenue of 584 million yuan, a 49.90% increase quarter-on-quarter, with significant growth in intellectual property licensing fees [24] - Dream Network Technology plans to establish a high-end equipment industry investment fund with a target fundraising of 2 billion yuan [26] - Hefei Urban Construction and China Real Estate Development won land use rights for a residential plot in Hefei for 980 million yuan [28] Group 5 - Lu Kang Pharmaceutical's subsidiary received a drug registration certificate for a new medication for erectile dysfunction [28] - Lifan Pharmaceutical's Mesalazine enteric-coated tablets received a drug registration certificate for treating ulcerative colitis [29] - Yahu Pharmaceutical's APL-1401 clinical trial for ulcerative colitis showed positive preliminary results [30]

Key Points - Tibet Tourism may apply for suspension of trading if significant abnormalities occur in stock transactions [1] - Southern Road Machinery's stock price has deviated from its fundamental situation [1] - Industrial Fulian's major customers and products have not undergone significant changes [1] - Yingweike has established a relatively complete liquid cooling technology and product solution capability [1] - Victory Energy's operational situation remains normal with no significant changes in the internal and external business environment [1] - Qizheng Tibetan Medicine's operational situation is normal with no significant changes in the internal and external business environment [1] - Dongxin Co. states that its investment in Shanghai Lishuan's chip products is not applicable for large model computing clusters [1] - Guosheng Co. has obtained project filing related to PEEK from its wholly-owned subsidiary [1] - Action Education's actual controller proposed a mid-term dividend of 10 yuan per 10 shares [1] Mergers and Acquisitions - Darui Electronics plans to acquire 80% of Weiste's equity through capital increase and share acquisition [1] - Dashengda intends to acquire 30% equity of Thailand's Far East [1] Financing - Aoshikang plans to issue convertible bonds not exceeding 1 billion yuan for high-end printed circuit board projects [1] - Sixuan New Materials intends to raise no more than 466 million yuan through a private placement [1] - Changhua Chemical plans to raise no more than 230 million yuan for a carbon dioxide polyether project [1] Share Buybacks and Reductions - Fuanna plans to repurchase shares worth between 55.85 million and 104 million yuan [1] - Jiangnan Yifan's board member intends to increase his stake in the company [1] - Jieya Co. and its concerted parties plan to reduce their holdings by no more than 4.95% [1] - Other companies including Tongda Co., Haohan Deep, and Wanhu Chemical also plan to reduce their holdings [1] Operational Data - Sinopec expects a net profit decline of 39.5% to 43.7% year-on-year for the first half of the year [1] - Qingdao Bank reported a net profit of 3.065 billion yuan for the first half, up 16.05% year-on-year [1] - Daodaquan's net profit increased by 563.15% year-on-year, proposing a dividend of 1.76 yuan per 10 shares [1] - Zhengdan Co. reported a net profit increase of 120.35% year-on-year, proposing a dividend of 3 yuan per 10 shares [1] - Other companies reported varying profit changes, including losses and significant increases [1] Contracts and Major Investments - Sanhui Electric signed a framework contract for robot equipment sales [1] - Zhejiang University Network New's subsidiary won a smart engineering project worth 94.2712 million yuan [1] - New Aluminum Times plans to invest no less than 500 million yuan in a project for lightweight, high-strength auto parts [1] - Zhishang Technology will use part of its raised funds for a smart manufacturing production base in Vietnam [1]

Group 1 - The company, Hefei Lifan Pharmaceutical Co., Ltd., has received the drug registration certificate for Mesalazine enteric-coated tablets from the National Medical Products Administration [1] - Mesalazine is a non-steroidal anti-inflammatory drug that significantly inhibits inflammation in the intestinal mucosa, suitable for treating acute episodes of ulcerative colitis and maintaining remission, as well as treating acute episodes of Crohn's disease [1] - The approval of Mesalazine enteric-coated tablets will enhance the company's product pipeline and market competitiveness, with four other domestic companies holding the same specification drug approval and three others holding different specifications [1]

Core Points - Recently, the company received the drug registration certificate for Mesalazine enteric-coated tablets from the National Medical Products Administration [2] Company Summary - The approval of the drug registration certificate is a significant milestone for the company, indicating progress in its product development and regulatory compliance [2]

Core Viewpoint - The company has received approval from the National Medical Products Administration for the registration certificate of Mesalazine enteric-coated tablets, indicating a significant advancement in its product offerings [1] Company Summary - The approved product, Mesalazine, is a non-steroidal anti-inflammatory drug that inhibits the synthesis of prostaglandins and the formation of inflammatory mediators such as leukotrienes, thereby significantly suppressing inflammation in the intestinal mucosa [1] - Mesalazine enteric-coated tablets are indicated for the treatment of acute exacerbations of ulcerative colitis and for maintenance therapy to prevent recurrence, as well as for the treatment of acute exacerbations of Crohn's disease [1] - The original developer of Mesalazine is the German company Fuchs Pharma GmbH [1]

Core Viewpoint - The company, Lifan Pharmaceutical, has received approval from the National Medical Products Administration for the registration certificate of Mesalazine enteric-coated tablets, indicating a significant advancement in its product offerings [1]. Group 1: Product Approval - The approval pertains to Mesalazine, a non-steroidal anti-inflammatory drug that inhibits the synthesis of prostaglandins and the formation of inflammatory mediators such as leukotrienes, thereby significantly suppressing inflammation in the intestinal mucosa [1]. - Mesalazine enteric-coated tablets are indicated for the treatment of acute exacerbations of ulcerative colitis and for maintenance therapy to prevent recurrence, as well as for the treatment of acute exacerbations of Crohn's disease [1]. - The original developer of Mesalazine is the German company, Ferring Pharmaceuticals [1].